Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. In clinical trials, a total of 1994 subjects with plaque psoriasis were treated with ILUMYA™, of which 1083 subjects were treated with ILUMYA™ 100 mg. Of these, 672 subjects were exposed for at least 12 months, 587 for 18 months, and 469 for 24 months. Data from 3 placebo-controlled trials (Trials 1, 2, and 3) in 705 subjects (mean age 46 years, 71% males, 81% white) were pooled to evaluate the safety of ILUMYA™ (100 mg administered subcutaneously at Weeks 0 and 4, followed by every 12 weeks [Q12W]).1
*From a post hoc pooled analysis extension study of reSURFACE 1 and 2. No imputation of missing data.
†Extended MACE includes non-fatal myocardial infarction, non-fatal stroke, unstable angina, coronary revascularization, resuscitated cardiac arrest, and CV deaths that are confirmed as “cardiovascular” or “sudden.”
‡Five subjects in the ILUMYA™ 100 mg group experienced non-treatment-related fatal AEs.
§AEs of interest include: Serious infections, malignancies, non-melanoma skin cancer, melanoma, extended MACE, deaths, injection site reactions, and drug-related hypersensitivity AEs.
AE=adverse event; CV=cardiovascular; MACE=major adverse cardiovascular events.
SAY YES TO A BIOLOGIC WITH TRIAL RESULTS THAT DEMONSTRATED:
- One contraindication1,7
ILUMYA™ has a hypersensitivity warning due to cases of angioedema and urticaria that occurred. Hypersensitivity reactions occurred at a rate of 0.1% for ILUMYA™ patients and 0.3% for placebo‖
‖No hospitalizations were required.
- Pretreatment evaluation limited to initial TB screening1
- No routine lab monitoring required1
INDICATION AND IMPORTANT SAFETY INFORMATION
ILUMYA™ (tildrakizumab-asmn) is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
ILUMYA™ is contraindicated in patients with a previous serious hypersensitivity reaction to tildrakizumab or to any of the excipients.
WARNINGS AND PRECAUTIONS
Cases of angioedema and urticaria occurred in ILUMYA™-treated subjects in clinical trials. If a serious allergic reaction occurs, discontinue ILUMYA™ immediately and initiate appropriate therapy.
ILUMYA™ may increase the risk of infection. Treatment with ILUMYA™ should not be initiated in patients with a clinically important active infection until the infection resolves or is adequately treated.
Consider the risks and benefits of treatment prior to prescribing ILUMYA™ in patients with a chronic infection or a history of recurrent infection. Instruct patients receiving ILUMYA™ to seek medical help if signs or symptoms of clinically important chronic or acute infection occur. If a patient develops a clinically important or serious infection, or is not responding to standard therapy, closely monitor and consider discontinuation of ILUMYA™ until the infection resolves.
Pretreatment Evaluation for Tuberculosis
Evaluate patients for tuberculosis (TB) infection prior to initiating treatment with ILUMYA™. Do not administer ILUMYA™ to patients with active TB infection. Initiate treatment of latent TB prior to administering ILUMYA™. Consider anti-TB therapy prior to initiation of ILUMYA™ in patients with a past history of latent or active TB in whom an adequate course of treatment cannot be confirmed. Patients receiving ILUMYA™ should be monitored closely for signs and symptoms of active TB during and after treatment.
Prior to initiating therapy with ILUMYA™, consider completion of all age-appropriate immunizations according to current immunization guidelines. Patients treated with ILUMYA™ should not receive live vaccines.
The most common (≥1%) adverse reactions associated with ILUMYA™ treatment that were more frequent than in the placebo group are upper respiratory infections, injection-site reactions, and diarrhea.
Please see full Prescribing Information.
References: 1. ILUMYA™ [package insert]. Princeton, NJ: Sun Pharmaceuticals, Inc. 2. Skyrizi™ (risankizumab-rzaa) [package insert]. North Chicago, IL: AbbVie, Inc. 3. Tremfya® (guselkumab) [prescribing information]. Horsham, PA:. Janssen Biotech, Inc. 4. Thaçi D, Iversen L, Pau-Charles I, et al. Long-term efficacy and safety of tildrakizumab in patients with moderate-to-severe psoriasis who were responders at week 28: pooled analysis through 3 years (148 weeks) from reSURFACE 1 and reSURFACE 2 phase 3 trials. Paper presented at: 27th Congress of the European Academy of Dermatology and Venereology (EADV); September 12-16, 2018; Paris, France. 5. Gooderham M, Papp KA, Blauvelt A, et al. Efficacy and safety of long-term tildrakizumab for plaque psoriasis: 3-year results from reSURFACE 2. Poster presented at:. American Academy of Dermatology Annual Meeting; March 1-5, 2019; Washington, DC. 6. Tyring SK, Spelman L, Igarashi A, et al. Efficacy and safety of long-term tildrakizumab for plaque psoriasis: 3-year results from reSURFACE 1. Poster presented at:. American Academy of Dermatology Annual Meeting; March 1-5, 2019; Washington, DC. 7. Data on File. Sun Pharmaceutical Industries, Inc. 8. Belinchón I, Rivera R, Blanch C, Comellas M, Lizán L. Adherence, satisfaction and preferences for treatment in patients with psoriasis in the European Union: a systematic review of the literature. Patient Prefer Adherence. 2016;10:2357-2367.